ATE353657T1 - Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma - Google Patents

Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma

Info

Publication number: ATE353657T1
Authority: AT; Austria
Prior art keywords: host; antigen; oligonucleotides; prevent; methods
Prior art date: 1997-09-05

Application number

AT98945877T

Other languages

English (en)

Inventor

Eyal Raz

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-05

Filing date

1998-09-04

Publication date

2007-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25454211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353657(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-04 Application filed by Univ California filed Critical Univ California

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE353657T1 publication Critical patent/ATE353657T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
208000006673 asthma Diseases 0.000 title 1
229960001438 immunostimulant agent Drugs 0.000 title 1
239000000427 antigen Substances 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
230000003308 immunostimulating effect Effects 0.000 abstract 2
230000004043 responsiveness Effects 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 1
210000003714 granulocyte Anatomy 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000001235 sensitizing effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

AT98945877T 1997-09-05 1998-09-04 Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma ATE353657T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92712097A	1997-09-05	1997-09-05

Publications (1)

Publication Number	Publication Date
ATE353657T1 true ATE353657T1 (de)	2007-03-15

Family

ID=25454211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98945877T ATE353657T1 (de)	1997-09-05	1998-09-04	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma

Country Status (12)

Country	Link
US (3)	US6498148B1 (de)
EP (2)	EP1872786A1 (de)
JP (1)	JP4663113B2 (de)
AT (1)	ATE353657T1 (de)
AU (1)	AU757175B2 (de)
CA (1)	CA2302805A1 (de)
CY (1)	CY1106571T1 (de)
DE (1)	DE69837094T2 (de)
DK (1)	DK1009413T3 (de)
ES (1)	ES2283070T3 (de)
PT (1)	PT1009413E (de)
WO (1)	WO1999011275A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109469A1 (en) *	1993-08-26	2003-06-12	Carson Dennis A.	Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030078223A1 (en) *	1996-01-30	2003-04-24	Eyal Raz	Compositions and methods for modulating an immune response
CA2244946C (en) *	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998016247A1 (en) *	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP4391592B2 (ja)	1996-10-25	2009-12-24	スリーエムカンパニー	Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
PT1009413E (pt) *	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
AU760795B2 (en) *	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
WO2000020039A1 (en) *	1998-10-05	2000-04-13	The Regents Of The University Of California	Methods and adjuvants for stimulating mucosal immunity
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
AU4031700A (en) *	1999-04-06	2000-11-02	East Carolina University	Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion
US6977245B2 (en) *	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (de)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
US7479285B1 (en)	1999-08-19	2009-01-20	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2493301A (en) *	1999-12-28	2001-07-09	Murdoch Childrens Research Institute, The	A method of therapy and prophylaxis of inflammation
WO2001051500A1 (en)	2000-01-14	2001-07-19	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6552006B2 (en)	2000-01-31	2003-04-22	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) *	2000-03-10	2002-08-08	Nest Gary Van	Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) *	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7157437B2 (en) *	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en)	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
WO2001085910A2 (en) *	2000-05-05	2001-11-15	The Regents Of The University Of California	Agents that modulate dna-pk activity and methods of use thereof
WO2002016549A2 (en) *	2000-08-25	2002-02-28	Yeda Research And Development Co. Ltd.	METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
EP1364010B1 (de) *	2000-12-27	2010-06-16	Dynavax Technologies Corporation	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
US20040110846A1 (en) *	2001-01-30	2004-06-10	Beatrice Leveugle	Perylenequinones for use with immunotherapy agents
EP1369127B1 (de) *	2001-02-20	2010-04-14	MARUHO Co., Ltd.	Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
KR100985457B1 (ko)	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) *	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
AU2002326561B2 (en)	2001-08-07	2008-04-03	Dynavax Technologies Corporation	Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en)	2001-08-14	2008-04-08	The United States Of America As Represented By Secretary Of The Department Of Health And Human Services	Method for rapid generation of mature dendritic cells
EA007232B1 (ru)	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
EP1450856B1 (de)	2001-09-14	2009-11-11	Cytos Biotechnology AG	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
DE10229872A1 (de) *	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
US7884083B2 (en)	2002-08-12	2011-02-08	Dynavax Technologies Corporation	Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US8263091B2 (en)	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004041183A2 (en) *	2002-11-01	2004-05-21	The Regents Of The University Of California	Methods of treating pulmonary fibrotic disorders
AU2003304107B2 (en)	2002-11-01	2008-05-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
WO2006050498A2 (en)	2004-11-02	2006-05-11	Archemix Corp.	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) *	2002-11-21	2018-10-16	Archemix Llc	Aptamers comprising CPG motifs
US8039443B2 (en) *	2002-11-21	2011-10-18	Archemix Corporation	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en)	2002-11-21	2014-10-07	Archemix Llc	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050124565A1 (en) *	2002-11-21	2005-06-09	Diener John L.	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
DK1992635T3 (da)	2002-12-23	2012-03-05	Dynavax Tech Corp	Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
US7625872B2 (en)	2002-12-23	2009-12-01	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
CN101675993A (zh)	2003-03-26	2010-03-24	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
EP1608403A2 (de) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
EP1620547B1 (de)	2003-04-21	2014-06-18	Archemix LLC	Stabilisierte aptamere für blutplättchen-wachstumsfaktor und ihre verwendung als onkologietherapeutika
US20060193821A1 (en) *	2004-03-05	2006-08-31	Diener John L	Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
EP1756138A4 (de) *	2004-03-05	2009-07-01	Archemix Corp	Auf die familie menschlicher il-12-cytokine gerichtete aptamere und deren verwendung als therapeutika gegen autoimmunkrankheiten
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
US7579450B2 (en) *	2004-04-26	2009-08-25	Archemix Corp.	Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
JP5331340B2 (ja)	2004-05-18	2013-10-30	バイカルインコーポレイテッド	インフルエンザウィルスワクチン組成物、及びその使用方法
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
KR20070110901A (ko)	2005-03-04	2007-11-20	다이나박스 테크놀로지 코퍼레이션	항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
EP1874325A2 (de) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
AU2006265896B2 (en)	2005-06-30	2012-05-31	Archemix Corp.	Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
US8101385B2 (en)	2005-06-30	2012-01-24	Archemix Corp.	Materials and methods for the generation of transcripts comprising modified nucleotides
US8506931B2 (en) *	2005-08-10	2013-08-13	Quest Pharmatech Inc.	Perylenequinone derivatives and uses thereof
AU2006325225B2 (en)	2005-12-14	2013-07-04	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
DK2034015T3 (da)	2006-05-31	2012-10-15	Toray Industries	Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
SI2032592T1 (sl)	2006-06-12	2013-10-30	Cytos Biotechnology Ag	Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
US8454991B2 (en) *	2006-07-24	2013-06-04	Quest Pharmatech Inc.	Method and device for photodynamic therapy
JP2010507361A (ja)	2006-07-31	2010-03-11	キュアバックゲーエムベーハー	具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
WO2008073661A2 (en)	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5721441B2 (ja)	2008-01-31	2015-05-20	キュアバックゲーエムベーハーＣｕｒｅｖａｃＧｍｂｈ	免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
BRPI0910036B8 (pt) *	2008-03-25	2021-05-25	Juvaris Biotherapeutics Inc	kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina
AU2009246169B2 (en)	2008-05-15	2015-01-22	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US8598327B2 (en)	2009-08-18	2013-12-03	Baxter International Inc.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
NZ598557A (en) *	2009-08-18	2013-08-30	Baxter Int	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011109833A2 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
EP2449113B8 (de)	2010-07-30	2015-11-25	CureVac AG	Komplexierung von nucleinsäuren mit disulfid-vernetzten kationischen bestandteilen zur transfektion und immunstimulation
AU2012214148A1 (en)	2011-02-11	2013-08-29	Baxter Healthcare S.A.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2968510B1 (de)	2013-03-14	2019-10-09	President and Fellows of Harvard College	Zusammensetzungen von nanopartikeln
BR112016003361A2 (pt)	2013-08-21	2017-11-21	Curevac Ag	vacina do vírus sincicial respiratório (rsv)
WO2015149944A2 (en)	2014-04-01	2015-10-08	Curevac Gmbh	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
EP3302501B1 (de)	2015-05-29	2021-09-22	Merck Sharp & Dohme Corp.	Kombination aus einem pd-1-antagonisten und cpg-c-typ-oligonukleotid zur behandlung von krebs
CN111840309A (zh) *	2020-08-19	2020-10-30	四川大学华西医院	鸟嘌呤核苷的新用途
US20250009731A1 (en)	2021-11-08	2025-01-09	Nurix Therapeutics, Inc.	Toll-like receptor therapy combinations with cbl-b inhibitor compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1234718A (en)	1914-03-21	1917-07-31	Int Harvester Canada	Buckle.
US3596660A (en) *	1969-05-12	1971-08-03	Illinois Tool Works	Injection device
US3725545A (en)	1971-02-03	1973-04-03	R Maes	Enhancement of antibody production by nucleic acid-polycation complexes
US3906092A (en)	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5268365A (en)	1988-03-11	1993-12-07	Rudolph Frederick B	Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance
US5750666A (en) *	1988-05-26	1998-05-12	Competitve Technologies, Inc.	Polynucleotide phosphorodithioate compounds
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
JPH09501936A (ja)	1993-08-26	1997-02-25	ザリージェンツオブザユニバーシティオブカリフォルニア	生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5972693A (en) *	1995-10-24	1999-10-26	Curagen Corporation	Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
CA2244946C (en) *	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998016247A1 (en) *	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2281838A1 (en) *	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
JP2001526688A (ja)	1997-05-19	2001-12-18	メルクエンドカンパニーインコーポレーテッド	オリゴヌクレオチドアジュバント
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1998055609A1 (en) *	1997-06-06	1998-12-10	The Regents Of The University Of California	Inhibitors of dna immunostimulatory sequence activity
PT1009413E (pt) *	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US20030103938A1 (en) *	2001-05-09	2003-06-05	Alk-Abello A/S	Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US8946387B2 (en) *	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
BRPI0512110A (pt) *	2004-06-15	2007-10-23	Idera Pharmaceutical Inc	multìmeros de oligonucleotìdeos imunoestimulatórios
WO2006091915A2 (en) *	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
US20090176696A1 (en) *	2006-04-18	2009-07-09	The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth	Methods And Compositions For Modulating An Immune Response

1998
- 1998-09-04 PT PT98945877T patent/PT1009413E/pt unknown
- 1998-09-04 DE DE69837094T patent/DE69837094T2/de not_active Expired - Lifetime
- 1998-09-04 JP JP2000508377A patent/JP4663113B2/ja not_active Expired - Lifetime
- 1998-09-04 AU AU93023/98A patent/AU757175B2/en not_active Expired
- 1998-09-04 WO PCT/US1998/018382 patent/WO1999011275A2/en not_active Ceased
- 1998-09-04 CA CA002302805A patent/CA2302805A1/en not_active Abandoned
- 1998-09-04 DK DK98945877T patent/DK1009413T3/da active
- 1998-09-04 EP EP07001453A patent/EP1872786A1/de not_active Withdrawn
- 1998-09-04 EP EP98945877A patent/EP1009413B1/de not_active Revoked
- 1998-09-04 ES ES98945877T patent/ES2283070T3/es not_active Expired - Lifetime
- 1998-09-04 AT AT98945877T patent/ATE353657T1/de active
1999
- 1999-01-21 US US09/235,742 patent/US6498148B1/en not_active Expired - Lifetime
2002
- 2002-08-26 US US10/229,208 patent/US20030092663A1/en not_active Abandoned
2007
- 2007-05-09 CY CY20071100623T patent/CY1106571T1/el unknown
- 2007-08-06 US US11/834,206 patent/US20090131347A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1009413T3 (da)	2007-06-11
HK1029515A1 (en)	2001-04-06
US6498148B1 (en)	2002-12-24
JP2002500159A (ja)	2002-01-08
PT1009413E (pt)	2007-05-31
EP1009413A2 (de)	2000-06-21
EP1872786A1 (de)	2008-01-02
CA2302805A1 (en)	1999-03-11
ES2283070T3 (es)	2007-10-16
WO1999011275A3 (en)	1999-06-03
WO1999011275A2 (en)	1999-03-11
AU757175B2 (en)	2003-02-06
US20030092663A1 (en)	2003-05-15
EP1009413B1 (de)	2007-02-14
JP4663113B2 (ja)	2011-03-30
CY1106571T1 (el)	2012-01-25
US20090131347A1 (en)	2009-05-21
DE69837094D1 (de)	2007-03-29
WO1999011275A9 (en)	1999-07-08
DE69837094T2 (de)	2007-08-30
AU9302398A (en)	1999-03-22

Legal Events

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1009413

Country of ref document: EP

Publication	Publication Date	Title
DE69837094D1 (de)	2007-03-29	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
DE69014137D1 (de)	1994-12-22	Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
TR199902124T2 (xx)	2000-06-21	�ltihapl� hastal�klar�n tedavisinde yararl� k��k molek�ller.
ATE190496T1 (de)	2000-04-15	Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE319474T1 (de)	2006-03-15	Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE69733145D1 (de)	2005-06-02	Verfahren zur behandlung von allergischen lungenkrankheiten
WO2000052054A3 (en)	2001-08-23	Antibodies for cancer therapy and diagnosis
TR199902803T2 (xx)	2000-07-21	VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
NO993847D0 (no)	1999-08-10	Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
DE69631478D1 (de)	2004-03-11	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE207356T1 (de)	2001-11-15	Verwendung von tiagabin zur behandlung von schlafstörungen
DE69939312D1 (de)	2008-09-25	Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE69826711D1 (de)	2004-11-04	Verfahren zur behandlung von pigmentierten krebszellen durch photodynamische therapie
EP1011644A4 (de)	2006-02-08	Verfahren und apparat zur behandlung der parkinson'schen krankheit
DE69729004D1 (de)	2004-06-09	Photodynamische therapie zur behandlung von osteosrthritis
DE69635305D1 (de)	2006-03-02	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE50014268D1 (de)	2007-05-31	Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
ATE281841T1 (de)	2004-11-15	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
CY1105549T1 (el)	2010-07-28	Καινουργια μεθοδος θεραπειας
WO2003040725A3 (en)	2003-12-04	Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
RU95105747A (ru)	1997-06-10	Способ лечения алкогольной зависимости и антиалкогольная композиция
RU95113130A (ru)	1997-07-27	Способ аэрозольтерапии
ATE145335T1 (de)	1996-12-15	Kreuzreaktive immunisierung gegen influenza
RU95118494A (ru)	1997-10-10	Способ лечения летней формы псориаза